US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
CA2097617A1
(en)
*
|
1990-11-23 |
1992-05-23 |
Brian Seed |
Inhibition of cell adhesion protein-carbohydrate interactions
|
US5401489A
(en)
*
|
1991-05-01 |
1995-03-28 |
University Of New Mexico |
Biomodulators as universal imaging agents
|
US5364612A
(en)
*
|
1991-05-06 |
1994-11-15 |
Immunomedics, Inc. |
Detection of cardiovascular lesions
|
US5919455A
(en)
*
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5888773A
(en)
*
|
1994-08-17 |
1999-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of producing single-chain Fv molecules
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US5559099A
(en)
*
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
US5545553A
(en)
*
|
1994-09-26 |
1996-08-13 |
The Rockefeller University |
Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
|
US5874540A
(en)
*
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
SE503711C2
(en)
*
|
1994-12-14 |
1996-08-12 |
Medicarb Ab |
Multistage procedure for coating an intraocular lens
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US5770442A
(en)
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
US6416714B1
(en)
*
|
1995-04-25 |
2002-07-09 |
Discovery Partners International, Inc. |
Remotely programmable matrices with memories
|
US5751629A
(en)
|
1995-04-25 |
1998-05-12 |
Irori |
Remotely programmable matrices with memories
|
US5874214A
(en)
|
1995-04-25 |
1999-02-23 |
Irori |
Remotely programmable matrices with memories
|
US6329139B1
(en)
|
1995-04-25 |
2001-12-11 |
Discovery Partners International |
Automated sorting system for matrices with memory
|
US6331273B1
(en)
|
1995-04-25 |
2001-12-18 |
Discovery Partners International |
Remotely programmable matrices with memories
|
US6017496A
(en)
|
1995-06-07 |
2000-01-25 |
Irori |
Matrices with memories and uses thereof
|
SI1445322T2
(en)
|
1995-06-15 |
2012-10-30 |
Crucell Holland Bv |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
AU702975B2
(en)
*
|
1995-09-22 |
1999-03-11 |
Immunomedics Inc. |
Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
|
WO1997023237A1
(en)
|
1995-12-22 |
1997-07-03 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
JP2000511403A
(en)
*
|
1996-03-20 |
2000-09-05 |
イムノメディクス,インコーポレイテッド |
Humanization of anti-carcinoembryonic antigen anti-idiotype antibodies and their use as tumor vaccines and for targeting applications
|
ATE267610T1
(en)
*
|
1996-03-20 |
2004-06-15 |
Immunomedics Inc |
GLYCOSYLATED IGG ANTIBODIES
|
US5891506A
(en)
*
|
1996-08-09 |
1999-04-06 |
Medtronic, Inc. |
Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices
|
CA2257357C
(en)
*
|
1996-06-07 |
2010-04-13 |
Neorx Corporation |
Humanized antibodies with modified glycosylation
|
US5861308A
(en)
*
|
1996-08-21 |
1999-01-19 |
Ludwig Institute For Cancer Research |
Isolated nucleic acids associated with T cell activation and uses thereof
|
US6136274A
(en)
*
|
1996-10-07 |
2000-10-24 |
Irori |
Matrices with memories in automated drug discovery and units therefor
|
JP2001505194A
(en)
*
|
1996-11-05 |
2001-04-17 |
ブリストル―マイヤーズ・スクイブ・カンパニー |
Branched peptide linker
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
US5816259A
(en)
*
|
1997-01-13 |
1998-10-06 |
Rose; Samuel |
Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
|
ATE427966T1
(en)
*
|
1997-02-11 |
2009-04-15 |
Immunomedics Inc |
STIMULATION OF AN IMMUNE RESPONSE THROUGH ANTIBODIES LABELED WITH THE ALPHA-GALACTOSYLE PITOPOPE
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
ES2215295T3
(en)
|
1997-02-21 |
2004-10-01 |
Genentech, Inc. |
CONJUGATES OF POLYMERS AND ANTIBODY FRAGMENTS.
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6306393B1
(en)
*
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6004529A
(en)
*
|
1997-04-11 |
1999-12-21 |
Nycomed Imaging As |
Chelating agents
|
WO1998049198A1
(en)
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
US6630302B1
(en)
|
1997-07-25 |
2003-10-07 |
The Trustees Of Boston University |
Methods and compositions for determining species of bacteria and fungi
|
US6673538B1
(en)
|
1997-07-25 |
2004-01-06 |
The Trustees Of Boston University |
Methods and compositions for designing vaccines
|
US6953675B2
(en)
*
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US6512098B2
(en)
*
|
1998-07-02 |
2003-01-28 |
Genencor International, Inc. |
Chemically modified proteins with a carbohydrate moiety
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
WO2000006243A2
(en)
|
1998-07-28 |
2000-02-10 |
Innerdyne, Inc. |
Absorbable brachytherapy and chemotherapy delivery devices and methods
|
JP2002525065A
(en)
|
1998-09-11 |
2002-08-13 |
ジェンベク、インコーポレイティッド |
Adenoviruses selectively targeted
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US20030099629A1
(en)
*
|
1999-03-11 |
2003-05-29 |
Immunomedics, Inc. |
Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
WO2003104467A1
(en)
*
|
2002-04-25 |
2003-12-18 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
US7018810B1
(en)
*
|
1999-12-07 |
2006-03-28 |
Amgen Inc. |
Chordin-like molecules and uses thereof
|
US20030023043A1
(en)
*
|
2000-03-02 |
2003-01-30 |
Kazuhisa Uchida |
Method of separating and purifying protein
|
EP1315699B1
(en)
*
|
2000-03-22 |
2013-01-02 |
Solulink, Incorporated |
Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
WO2001092549A2
(en)
*
|
2000-05-31 |
2001-12-06 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
CA2410906C
(en)
|
2000-06-02 |
2012-10-02 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
CN1592645A
(en)
*
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory anti-body combination
|
US20040033605A1
(en)
*
|
2000-09-20 |
2004-02-19 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells
|
DE60138403D1
(en)
*
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST
|
EP1358344B1
(en)
*
|
2001-01-08 |
2007-08-29 |
Applera Corporation |
Dendritic chemiluminescent substrates
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
CA2438682A1
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
DE60237810D1
(en)
*
|
2001-04-03 |
2010-11-11 |
Thermo Finnigan Llc |
SIMPLIFICATION OF COMPLEX PEPTIDE MIXTURES AND KITS
|
WO2002087497A2
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
|
EP1389090A2
(en)
*
|
2001-04-26 |
2004-02-18 |
Board of Regents, The University of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
WO2002092771A2
(en)
|
2001-05-11 |
2002-11-21 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
GB0112844D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Psimei Pharmaceuticals Plc |
Neutron capture therapy
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7696163B2
(en)
*
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7179617B2
(en)
*
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US20050069962A1
(en)
|
2001-10-12 |
2005-03-31 |
Archer Robert M |
Antibody complexes and methods for immunolabeling
|
US8323903B2
(en)
*
|
2001-10-12 |
2012-12-04 |
Life Technologies Corporation |
Antibody complexes and methods for immunolabeling
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
US20030135195A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Oscar Jimenez |
Highly lubricious hydrophilic coating utilizing dendrimers
|
JP4498746B2
(en)
|
2002-02-14 |
2010-07-07 |
イミューノメディクス、インコーポレイテッド |
Anti-CD20 antibody and fusion protein thereof and method of use
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
DE60325184D1
(en)
|
2002-03-01 |
2009-01-22 |
Immunomedics Inc |
RS7 ANTIBODY
|
ATE477276T1
(en)
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
WO2003079980A2
(en)
*
|
2002-03-19 |
2003-10-02 |
A & D Bioscience, Inc. |
Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
|
RU2004133765A
(en)
|
2002-04-19 |
2005-06-27 |
ЗАЙМОДЖЕНЕТИКС Инк. (US) |
CYTOKINE RECEPTOR
|
EP2301968A3
(en)
|
2002-06-14 |
2011-06-29 |
Immunomedics, Inc. |
Humanized monoclonal antibody HPAM4
|
AU2003299509A1
(en)
*
|
2002-06-21 |
2004-05-13 |
University Of Utah Research Foundation |
Crosslinked compounds and methods of making and using thereof
|
MXPA04012496A
(en)
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Pegylated factor vii glycoforms.
|
JP5138867B2
(en)
*
|
2002-08-01 |
2013-02-06 |
イミューノメディクス、インコーポレイテッド |
α-fetoprotein Immu31 antibody and fusion protein and method of use thereof
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
US7939304B2
(en)
*
|
2002-10-02 |
2011-05-10 |
Catalyst Biosciences, Inc. |
Mutant MT-SP1 proteases with altered substrate specificity or activity
|
US20060024289A1
(en)
*
|
2002-10-02 |
2006-02-02 |
Ruggles Sandra W |
Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
|
CA2501616C
(en)
|
2002-10-08 |
2015-05-12 |
Immunomedics, Inc. |
Antibody therapy
|
CN1723042B
(en)
*
|
2002-11-07 |
2010-12-01 |
得克萨斯大学体系董事会 |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
ES2345885T3
(en)
|
2002-11-15 |
2010-10-05 |
Novartis Vaccines And Diagnostics, Inc. |
METHODS TO PREVENT AND TREAT CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS.
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
CA2519092C
(en)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Branched water-soluble polymers and their conjugates
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
BRPI0410164A
(en)
|
2003-05-09 |
2006-05-16 |
Neose Technologies Inc |
compositions and methods for preparing human growth hormone glycosylation mutants
|
PL1639011T3
(en)
*
|
2003-06-30 |
2009-05-29 |
Domantis Ltd |
Pegylated single domain antibodies (dAb)
|
US9005625B2
(en)
*
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
CA2533878A1
(en)
*
|
2003-07-29 |
2005-09-22 |
Immunomedics, Inc. |
Fluorinated carbohydrate conjugates
|
EP1648512A4
(en)
|
2003-07-31 |
2009-01-21 |
Immunomedics Inc |
Anti-cd19 antibodies
|
US7083936B2
(en)
*
|
2003-08-01 |
2006-08-01 |
Beckman Coulter, Inc. |
Aminodextran compositions and conjugates and method of making and using them
|
US20080305992A1
(en)
*
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US7842661B2
(en)
*
|
2003-11-24 |
2010-11-30 |
Novo Nordisk A/S |
Glycopegylated erythropoietin formulations
|
US20080318850A1
(en)
*
|
2003-12-03 |
2008-12-25 |
Neose Technologies, Inc. |
Glycopegylated Factor Ix
|
US7956032B2
(en)
*
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
EP3476861A1
(en)
|
2004-01-07 |
2019-05-01 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
CA2552892C
(en)
|
2004-01-08 |
2014-08-05 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
EP3611273A1
(en)
|
2004-03-31 |
2020-02-19 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
SE0400886D0
(en)
*
|
2004-04-02 |
2004-04-02 |
Amersham Biosciences Ab |
Process of purification
|
CA2562729C
(en)
|
2004-04-12 |
2013-11-12 |
Sandra Waugh Ruggles |
Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
|
CN1296711C
(en)
*
|
2004-05-14 |
2007-01-24 |
沈阳迈迪生物医学技术有限公司 |
Breast cancer Her-2 immunohisto chemical diagnostic kit
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
US20100009902A1
(en)
*
|
2005-01-06 |
2010-01-14 |
Neose Technologies, Inc. |
Glycoconjugation Using Saccharyl Fragments
|
EP1858543B1
(en)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Glycopegylated granulocyte colony stimulating factor
|
WO2006094192A2
(en)
|
2005-03-03 |
2006-09-08 |
Immunomedics, Inc. |
Humanized l243 antibodies
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
EP1866427A4
(en)
*
|
2005-03-30 |
2010-09-01 |
Novo Nordisk As |
Manufacturing process for the production of peptides grown in insect cell lines
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US20080255026A1
(en)
*
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
US20110003744A1
(en)
*
|
2005-05-25 |
2011-01-06 |
Novo Nordisk A/S |
Glycopegylated Erythropoietin Formulations
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US8097237B2
(en)
*
|
2005-08-23 |
2012-01-17 |
Stc.Unm |
Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
|
JP4808453B2
(en)
*
|
2005-08-26 |
2011-11-02 |
株式会社荏原製作所 |
Polishing method and polishing apparatus
|
WO2007026972A2
(en)
*
|
2005-09-01 |
2007-03-08 |
Canon Kabushiki Kaisha |
Binding protein molecule
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
PE20100748A1
(en)
*
|
2005-12-12 |
2010-11-12 |
Hoffmann La Roche |
ANTI BETA-4-AMYLOID ANTIBODY CONTAINING GLYCOSYLATED ASPARAGINE IN THE VARIABLE REGION OF VH
|
EP2674440B1
(en)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
JP4546578B2
(en)
|
2006-07-05 |
2010-09-15 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
Protease screening method and protease identified thereby
|
CN101516388B
(en)
*
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
Glycosylation of peptides via O-linked glycosylation sequences
|
JP5406027B2
(en)
|
2006-08-04 |
2014-02-05 |
ノバルティス アーゲー |
EphB3-specific antibodies and uses thereof
|
AR062435A1
(en)
|
2006-08-18 |
2008-11-05 |
Xoma Technology Ltd |
PRLR SPECIFIC ANTIBODY (PROLACTIN RECEPTOR) AND ITS USES
|
US20080095414A1
(en)
*
|
2006-09-12 |
2008-04-24 |
Vladimir Desh |
Correction of functional nuclear imaging data for motion artifacts using anatomical data
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
US10925977B2
(en)
*
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
MX2009006034A
(en)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Antagonist antibodies against ephb3.
|
EP2126127B1
(en)
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
AU2008227123B2
(en)
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
DK2144923T3
(en)
|
2007-04-03 |
2013-05-13 |
Biogenerix Ag |
METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF
|
AU2014208212B2
(en)
*
|
2007-05-22 |
2016-07-28 |
Wyeth |
Improved processes for making hydrazides
|
ES2686019T3
(en)
|
2007-05-22 |
2018-10-16 |
Wyeth Llc |
Improved hydrazide manufacturing procedures
|
ES2551123T3
(en)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Improved process for the production of nucleotide sugars
|
EP2188311B1
(en)
|
2007-08-14 |
2016-10-05 |
Ludwig Institute for Cancer Research Ltd. |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
EP2242514B1
(en)
*
|
2008-01-30 |
2015-09-30 |
University Of Kansas |
Intralymphatic chemotherapy drug carriers
|
CN101965200B
(en)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
Conjugated factor VIII molecules
|
JP6049163B2
(en)
*
|
2008-07-21 |
2016-12-21 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
Antibody structural variants for improved therapeutic characteristics
|
DK3912643T3
(en)
|
2009-02-13 |
2022-10-17 |
Immunomedics Inc |
IMMUNOCONJUGATES WITH AN INTRACELLULAR-CLEAVABLE BOND
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
US8614185B2
(en)
*
|
2009-05-04 |
2013-12-24 |
Centocor Ortho Biotech Inc. |
Fusion proteins of alpha-MSH derivatives and Fc
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
TW201120210A
(en)
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
WO2011068845A1
(en)
|
2009-12-02 |
2011-06-09 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
EP2523680A4
(en)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
CN103119064B
(en)
|
2010-08-10 |
2018-09-04 |
葛莱高托普有限公司 |
Fab glycosylated antibodies
|
US8956859B1
(en)
|
2010-08-13 |
2015-02-17 |
Aviex Technologies Llc |
Compositions and methods for determining successful immunization by one or more vaccines
|
EP2704751B1
(en)
|
2011-05-02 |
2019-04-17 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
US10865383B2
(en)
|
2011-07-12 |
2020-12-15 |
Lineage Cell Therapeutics, Inc. |
Methods and formulations for orthopedic cell therapy
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
WO2013096455A1
(en)
|
2011-12-20 |
2013-06-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
WO2013177426A2
(en)
|
2012-05-24 |
2013-11-28 |
Dana-Farber Cancer Institute, Inc. |
Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
|
WO2014014518A1
(en)
|
2012-07-18 |
2014-01-23 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating, preventing and predicting risk of developing breast cancer
|
US9315567B2
(en)
|
2012-08-14 |
2016-04-19 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
PT2900277T
(en)
|
2012-12-13 |
2022-05-25 |
Immunomedics Inc |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
ES2819573T3
(en)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Method for Producing Antibody-SN-38 Immunoconjugates with a CL2A Linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
DK2991683T3
(en)
|
2013-05-02 |
2019-11-04 |
Glykos Finland Oy |
CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC CHARGE
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
AU2014332442B2
(en)
|
2013-08-26 |
2019-12-19 |
Biontech Research And Development, Inc. |
Nucleic acids encoding human antibodies to Sialyl-Lewis
|
WO2015050844A1
(en)
|
2013-10-01 |
2015-04-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer with atovaquone-related compounds
|
AU2015219495B2
(en)
|
2014-02-21 |
2019-11-21 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
WO2015149006A2
(en)
|
2014-03-27 |
2015-10-01 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
|
CA2950602C
(en)
|
2014-06-04 |
2021-07-20 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
EP3160504B1
(en)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
WO2015197919A1
(en)
|
2014-06-25 |
2015-12-30 |
Glykos Finland Oy |
Antibody drug conjugates binding to high-mannose n-glycan
|
AU2015282627B2
(en)
|
2014-06-30 |
2020-04-02 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
RS62986B1
(en)
|
2015-06-24 |
2022-03-31 |
Hoffmann La Roche |
Anti-transferrin receptor antibodies with tailored affinity
|
PT3313443T
(en)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
AR106189A1
(en)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
|
TWI747843B
(en)
|
2015-10-02 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
CN109310385A
(en)
|
2016-04-27 |
2019-02-05 |
免疫医疗公司 |
Anti- TROP-2-SN-38 antibody drug conjugate is used for the effect of checkpoint inhibitor recurrence/refractory tumors therapy
|
WO2017214186A1
(en)
|
2016-06-09 |
2017-12-14 |
University Of Leicester |
Monoclonal antibodies, compositions and methods for detecting mucin -like protein (mlp) as a biomarker for ovarian and pancreatic cancer
|
EP3600283A4
(en)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
|
CN110352201A
(en)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
The subcutaneous administration of antibody drug conjugate for cancer therapy
|
CA3062238A1
(en)
*
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
CN111630069A
(en)
|
2017-10-13 |
2020-09-04 |
勃林格殷格翰国际有限公司 |
Human antibodies to Thomsen-novell (Tn) antigens
|
EP4249002A3
(en)
|
2018-05-18 |
2023-11-22 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1- exatecan antibody-drug conjugate
|
CN109270064B
(en)
*
|
2018-11-12 |
2020-12-01 |
新乡医学院 |
Immunoprecipitation reagent based on dextran microspheres and preparation method and application thereof
|
AU2020248645A1
(en)
|
2019-03-27 |
2021-10-28 |
Tigatx, Inc. |
Engineered IgA antibodies and methods of use
|
JP2024514683A
(en)
*
|
2021-04-23 |
2024-04-02 |
ユニバーシティ オブ メリーランド, カレッジ パーク |
Fc glycan remodeling platform method for site-specific antibody conjugation and its applications
|
JPWO2022239720A1
(en)
|
2021-05-10 |
2022-11-17 |
|
|